HBP Helix BioPharma Corp

Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company
developing innovative drug candidates for the prevention and treatment of
cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of
the board effective July 17, 2014. Mr. Bastien has served as an independent
director of the Company since December 2013 and remains the Chair of the board's
Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim
Chair since December 2013 and remains a Director of the Company and President
and CEO.


"I am very pleased Mr. Bastien has accepted the role of board Chair," said Mr.
Verhagen. "As a result of his current service on Helix's Board we have already
experienced firsthand his vast amount of knowledge from his involvement in the
life science industry both in a leadership capacity and at the board level. I am
confident that Helix can only be strengthened going forward with Mr. Bastien as
Board Chair."


Following his appointment, Mr. Bastien said, "On behalf of the board, I would
like to thank Mr. Verhagen for his service as interim Chair during the past
seven months, and I thank the board of Helix for their confidence in me. I am
excited to work closely with both management and all board members to optimize
the development of Helix's oncology portfolio and to continue to work to create
value for patients and all stakeholders."


Mr. Bastien has served in leadership roles within the life sciences industry for
over 30 years, most recently as past President of Sanofi Canada and past
President of Jouveniel. He has also served in executive roles at CIBA Geigy in
Switzerland, Laboratoire Debat in Paris, IMS Canada in Montreal, and Eli Lilly
in Montreal. He currently serves as chairman of the board for two health care
companies and is a director of Bioniche Life Sciences. He previously served as
chairman of the board for two other biotech companies. 


About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field
of cancer therapy. The company is actively developing innovative products for
the prevention and treatment of cancer based on its proprietary technologies.
Helix's product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the
TSX and FSE under the symbol "HBP".



FOR FURTHER INFORMATION PLEASE CONTACT: 

Investor Relations:
Helix BioPharma Corp.
Tel: +1 (905) 841-2300
Email: ir@helixbiopharma.com

Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Helix BioPharma (TSX:HBP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024